The first batches of drugs manufactured by the new plant will be distributed in Switzerland and the European Union within two years.
Keystone
The pharmaceutical giant Novartis has announced plans to invest CHF90 million ($91.5 million) over three years on a production site for cell and gene therapies. The goal is to enable new treatments to be delivered in Europe.
The expansion will take place at the company’s Stein site in Aargau. As a first step, Novartis plans to create 260 new jobs and says there is potential to raise that number to 450 by 2021. Last year the company announced plans to slash 500 jobs at its Basel headquarters, but said at the time that it wanted to create 350 new positions, mainly in its biotech business.
The first batches of drugs manufactured by the new plant will be distributed in Switzerland and the European Union within two years, Novartis said in a statement on Monday.
“This investment illustrates the changes the sector is undergoing,” said Matthias Leuenberger, Head of Switzerland at Novartis. “As we invest in new highly specialised technologies, the importance of some traditional areas will diminish,” he said.
The announcement of the investment in Stein comes after the European Commission approved the company’s Kymriah cell therapyExternal link for the treatment of acute B-cell lymphoblastic leukemia in children and young adults up to 25 years.
Novartis already operates a plant in the US in Morris Plains, New Jersey, that specialises in the production of cell and gene therapies.
More
More
Novartis to shed 500 jobs in Basel
This content was published on
The Swiss pharmaceutical giant Novartis has announced that it plans to cut 500 jobs at its Basel headquarters in Switzerland over the next 18 months.
Trump tariffs: Swiss brands struggle to adapt to 39% tariff
This content was published on
Swiss brands like Victorinox, the manufacturer of the iconic pocket knife, are struggling to adapt to the 39% tariff imposed by the United States on imports of Swiss goods.
Fish and aquatic plants are under ‘severe pressure’ in Swiss rivers and lakes
This content was published on
Fish, aquatic plants and other animals in Swiss rivers, lakes and streams remain under 'severe pressure', according to the Federal Office for the Environment.
Swatch withdraws ‘slanted eyes’ ad after China uproar
This content was published on
The Swiss watch manufacturer Swatch has apologised and withdrawn an advertising campaign worldwide following accusations of racism in China. The ad features a model pulling the corners of his eyes.
Police identify bodies of three climbers who died in Swiss Alps
This content was published on
Police have formally identified the bodies of three climbers who died in the Upper Valais region in early August: they are from Germany, France and Austria.
Bern exhibition reunites Kirchner paintings after 92 years
This content was published on
The painting Sonntag der Bergbauern (Alpsonntag) [Sunday of the Mountain Farmers (Alp Sunday) by Ernst Ludwig Kirchner (1880-1938) is being transferred from Berlin to Bern to feature in an upcoming exhibition at Kunstmuseum Bern.
Voters approve extension of Engadine Airport in Switzerland
This content was published on
Residents in the Upper Engadine region gave the greenlight on Sunday to the expansion of the regional airport at Samedan, one of Europe’s highest airports (1,707 metres) that serves the nearby resorts of St Moritz and Davos.
Private equity group Advent to buy U-Blox for $1.3 billion
This content was published on
Private equity group Advent International has agreed to take over Switzerland's U-Blox Holding in a cash offer worth CHF1.05 billion ($1.30 billion).
Trump made direct financial demands during call with Swiss president
This content was published on
During the telephone call between Karin Keller-Sutter and Donald Trump on July 31, Trump demanded direct payments from Switzerland, according to an investigation by SonntagsBlick.
Demonstrators in Swiss capital demand better access to mental health care
This content was published on
Thousands of people demonstrated in Berne on Saturday afternoon against long waiting lists, the lack of therapy places and the absence of a clear pricing structure.
This content was published on
Swiss companies' expectations for salary growth are down by 0.3 percentage points compared to a year ago, according to a survey conducted by the Center for Economic Research (KOF).
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis: The making of a pharma giant
This content was published on
The company formed when Ciba Geigy and Sandoz merged and analysts say it’s a big success. The merger cost around 10,000 jobs but in the long-run more were created. The current CEO concedes that the merger also meant the loss of the Ciba corporate identity. Novartis’ profits shrank by a third in 2015, partly because…
This content was published on
The status of Novartis as a leading Big Pharma company is beyond doubt. But after five difficult years, critical choices about assets are looming.
Swiss pharma suspected of delaying generic competition
This content was published on
The United States Food and Drug Administration (FDA) lists Novartis and Roche among drug-makers suspected of hindering generic competition.
Export growth increasingly depends on pharmaceuticals
This content was published on
Swiss exports hit a record CHF210 billion ($211 billion) last year and the pharmaceutical sector was one of the big drivers.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.